biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Comment by TechnicalBuyon Jan 28, 2012 8:57am

221 Views

Post# 19460955

RE: RE: biOasis like Immunogen

jd, I think a take-over is a possibility, but we are far more likely to see an exclusive licensing deal first. This would only be fair to us as shareholders because a premature take-over might rob us of significant upside potential.

I found this article to be very useful in looking at valuations of companies that are similar to Bioasis. Of particular interest is Immunogen's $1 bn valuation based mostly on it's 'air to the throne' status for Herceptin....note that at a $1, biOasis' market cap is barely over $30 M. Even with the sp at $3 we are only at $100 mcap....